Acorda Therapeutics Overview
- Year Founded
-
1995
- Status
-
Acquired/Merged
- Employees
-
277
- Latest Deal Type
-
M&A
- Financing Rounds
-
27
- Investments
-
7
Acorda Therapeutics General Information
Description
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis. The company's Net product revenue is derived from the sales of Ampyra and Inbrija.
Contact Information
Website
www.acorda.com(Operating Subsidiary)
Corporate Office
- 2 Blue Hill Plaza
- 3rd Floor, Pearl River
- Ardsley, NY 10965
- United States
Corporate Office
- 2 Blue Hill Plaza
- 3rd Floor, Pearl River
- Ardsley, NY 10965
- United States
Acorda Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Acorda Therapeutics Comparisons
Industry
Financing
Details
Acorda Therapeutics Competitors (47)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novo Nordisk | Corporation | Bagsvaerd, Denmark | ||||
| Catalyst Pharmaceuticals | Corporation | Coral Gables, FL | ||||
| The Zambon Group | Private Debt Financed | Bresso, Italy | ||||
| Sanofi | Corporation | Paris, France | ||||
| SAGE Therapeutics | Formerly VC-backed | Cambridge, MA |
Acorda Therapeutics Patents
Acorda Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3606510-A1 | Sustained release compositions of 4-aminopyridine | Pending | 06-Apr-2017 | ||
| CA-3059180-A1 | Sustained release compositions of 4-aminopyridine | Active | 06-Apr-2017 | ||
| CA-3059180-C | Sustained release compositions of 4-aminopyridine | Active | 06-Apr-2017 | ||
| US-20180344649-A1 | Sustained release compositions of 4-aminopyridine | Inactive | 29-Sep-2015 | ||
| US-20210085614-A1 | Sustained release compositions of 4-aminopyridine | Inactive | 29-Sep-2015 | A61K9/2866 |
Acorda Therapeutics Executive Team (20)
| Name | Title | Board Seat |
|---|---|---|
| Ron Cohen MD | Founder, President, Board Member & Chief Executive Officer | |
| Michael Gesser | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | |
| Andrew Blight Ph.D | Chief Scientific Officer | |
| David Lawrence | Chief of Business Operations and Principal Accounting Officer | |
| Denise Duca | Executive Vice President, Human Resources |
Acorda Therapeutics Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Acorda Therapeutics | Founder, President, Board Member & Chief Executive Officer |
Acorda Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Acorda Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Acorda Therapeutics Investments & Acquisitions (7)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Biotie Therapies | 18-Apr-2016 | Biotechnology | |||
| Civitas Therapeutics | 23-Oct-2014 | Drug Delivery | |||
| NeurogesX | 10-Jul-2013 | Pharmaceuticals | |||
| Qutenza | 09-Jul-2013 | Buildings and Property | |||
| Neuronex | 21-Dec-2012 | Merger/Acquisition | Pharmaceuticals |
Acorda Therapeutics ESG
Risk Overview
Risk Rating
Updated June, 30, 2020
29.5 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,035
Rank
Percentile
Pharmaceuticals
Industry
of 806
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
Acorda Therapeutics FAQs
-
When was Acorda Therapeutics founded?
Acorda Therapeutics was founded in 1995.
-
Who is the founder of Acorda Therapeutics?
Ron Cohen MD is the founder of Acorda Therapeutics.
-
Who is the CEO of Acorda Therapeutics?
Ron Cohen MD is the CEO of Acorda Therapeutics.
-
Where is Acorda Therapeutics headquartered?
Acorda Therapeutics is headquartered in Ardsley, NY.
-
What is the size of Acorda Therapeutics?
Acorda Therapeutics has 277 total employees.
-
What industry is Acorda Therapeutics in?
Acorda Therapeutics’s primary industry is Pharmaceuticals.
-
Is Acorda Therapeutics a private or public company?
Acorda Therapeutics is a Private company.
-
What is the current valuation of Acorda Therapeutics?
The current valuation of Acorda Therapeutics is .
-
What is Acorda Therapeutics’s current revenue?
The current revenue for Acorda Therapeutics is .
-
How much funding has Acorda Therapeutics raised over time?
Acorda Therapeutics has raised $753M.
-
Who are Acorda Therapeutics’s investors?
BlackRock, Cross Atlantic Partners, EDBI, Easton Capital Investment Group, and Endpoint Late Stage Fund are 5 of 26 investors who have invested in Acorda Therapeutics.
-
Who are Acorda Therapeutics’s competitors?
Novo Nordisk, Catalyst Pharmaceuticals, The Zambon Group, Sanofi, and SAGE Therapeutics are some of the 47 competitors of Acorda Therapeutics.
-
When was Acorda Therapeutics acquired?
Acorda Therapeutics was acquired on 10-Jul-2024.
-
Who acquired Acorda Therapeutics?
Acorda Therapeutics was acquired by Merz Therapeutics (Germany).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
